# Johnson & Johnson (JNJ) Financial Model Free Excel 3-statement financial model and company analysis for Johnson & Johnson. - Canonical: https://finamodel.com/companies/johnson-johnson - Industry: Pharmaceuticals - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/JNJ.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for an equity research analyst covering Johnson & Johnson, focusing on the revenue transition from legacy blockbusters facing loss of exclusivity to new pipeline assets and recent MedTech acquisitions. ## Company Overview Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices. - Innovative Medicine (approx. 64% of revenue): Focuses on immunology, oncology, neuroscience, and cardiovascular therapies. - MedTech (approx. 36% of revenue): Provides products for surgery, orthopaedics, vision, and interventional solutions. - Key geographies: United States (approx. 55%), International (approx. 45%). - Business model type: Intellectual property-heavy in pharmaceuticals and manufacturing-intensive in medical devices. - Competitive position: Top-tier global pharmaceutical and medical device manufacturer, holding leading market shares in multiple myeloma, psoriasis, and electrophysiology. - Recent major events: The 2023 spinoff of the Consumer Health segment (Kenvue), and significant acquisitions including Abiomed, Shockwave Medical, V-Wave, and Halda Therapeutics. ## Revenue Deep Dive ### Innovative Medicine - Segment name: Innovative Medicine - Revenue driver formula: Patient Volume x Net Price per Treatment - Historical growth rate: 4% to 6% CAGR - Key growth levers and headwinds: Growth driven by Darzalex, Tremfya, and Erleada; major headwind is the loss of exclusivity for Stelara. - Pricing dynamics: Heavily regulated and subject to payer negotiations, rebates, and government pricing pressures (e.g. US Inflation Reduction Act). - Revenue recognition notes: Recognised upon delivery, net of estimated rebates, discounts, and returns. - Seasonality: Generally stable, though Q4 often sees slight variations due to payer budget cycles and rebate true-ups. ### MedTech - Segment name: MedTech - Revenue driver formula: Procedure Volume x Average Selling Price (ASP) - Historical growth rate: 5% to 7% CAGR (boosted by recent acquisitions) - Key growth levers and headwinds: Driven by electrophysiology and cardiovascular acquisitions (Abiomed, Shockwave); headwinds include hospital capital spending constraints and elective procedure deferrals. - Pricing dynamics: Contractual pricing with hospital networks and group purchasing organisations. - Revenue recognition notes: Recognised when control transfers to the customer, typically upon shipment or delivery to hospitals. - Seasonality: Q4 is typically the strongest quarter due to patients exhausting annual health insurance deductibles and scheduling elective surgeries. ## Cost Structure ### Variable Costs / COGS - COGS includes manufacturing costs, raw materials, direct labour, and fair value inventory step-ups from acquisitions. - Gross margin range: 66% to 70% (average approx. 68%). - Key input costs include active pharmaceutical ingredients, electronic components for devices, and logistics. - COGS scales linearly with MedTech volume but exhibits massive operating leverage in Innovative Medicine once manufacturing scale is reached. ### Operating Expenses - R&D: Typically 14% to 16% of revenue, covering clinical trials, pipeline development, and regulatory submissions. - SG&A: Typically 24% to 26% of revenue, driven by sales force compensation, marketing for new drug launches, and corporate overhead. - Depreciation & Amortisation: Approx. 5% to 7% of revenue, heavily skewed towards amortisation of acquired intangible assets. - In-Process R&D (IPR&D): Frequent one-time charges related to upfront payments for licensing deals and acquisitions. - Restructuring / one-time charges: Frequent adjustments for litigation reserves (e.g. talc liabilities) and integration costs. ### Margin Profile - Gross margin: 66% to 70%. - EBITDA margin: 32% to 35%. - Operating margin: 28% to 31%. - Net margin: 15% to 22% (highly variable due to one-time IPR&D and litigation charges). - Margin trend: Gross margins have faced slight compression recently due to inventory step-ups and product mix, but operating margins remain robust due to cost management. ## Balance Sheet Structure - Total assets: Approx. $190 billion to $195 billion. - Key asset categories: Cash and marketable securities, accounts receivable, inventory, property, plant and equipment, and massive intangible assets. - Goodwill & intangibles: Represent over 40% of total assets due to a history of large acquisitions. - Working capital profile: - Days Sales Outstanding (DSO): 55 to 65 days. - Days Inventory Outstanding (DIO): 100 to 115 days. - Days Payable Outstanding (DPO): 110 to 130 days. - Net working capital as % of revenue: Typically low single digits. - Working capital is generally a slight use of cash as the business grows, though strong payables management offsets inventory needs. - PP&E: Manufacturing facilities, surgical equipment, and research laboratories. - Right-of-use assets: Material but manageable, representing leased office and laboratory space. ## Capital Expenditure & Investment - Capex as % of revenue: 3% to 4.5%. - Maintenance capex vs. growth capex: Approximately 40% maintenance and 60% growth (new manufacturing lines for biologics). - Major capex programmes: Expanding biologic manufacturing capacity and robotic surgery development facilities. - M&A pattern: Transformational and bolt-on acquirer, frequently purchasing clinical-stage biotech and high-growth MedTech firms. - Typical acquisition multiple paid: Often 5x to 10x peak sales for pre-revenue or early-revenue biotech and MedTech assets. ## Debt & Capital Structure - Total debt: Approx. $35 billion to $40 billion. - Debt/EBITDA ratio: Approx. 1.0x to 1.5x. - Credit rating: AAA (one of the very few corporate issuers with this rating). - Key debt instruments: Senior unsecured notes and commercial paper. - Maturity profile: Well-laddered with a long average maturity profile. - Interest rate profile: Predominantly fixed-rate bonds. - Covenants: Very few restrictive financial covenants given the pristine credit rating. - Share repurchase programme: Active, typically offsetting dilution and returning excess cash. - Dividend policy: Dividend aristocrat with over 60 years of increases; payout ratio typically 45% to 55%, yielding approx. 3%. ## Cash Flow Characteristics - Operating cash flow conversion: OCF / Net Income is typically 1.2x to 1.5x, driven by high non-cash amortisation. - Free cash flow margin: 20% to 25%. - Major non-cash items: Depreciation, amortisation of intangibles, stock-based compensation, and IPR&D charges. - Working capital cash flow impact: Minor fluctuations, occasionally impacted by timing of rebate payments and litigation settlements. - Capex intensity: Low relative to cash generation. - Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than GAAP taxes due to R&D tax credits and the timing of deductibility for litigation payments. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, tax rates, and WACC. 2. **Revenue_Innovative_Medicine**: Build-up of pharmaceutical revenue by key therapeutic area (Oncology, Immunology, Neuroscience, Cardiovascular) and major blockbuster drugs (Darzalex, Stelara, Tremfya). 3. **Revenue_MedTech**: Build-up of device revenue by sub-segment (Surgery, Orthopaedics, Vision, Interventional Solutions) including recent acquisition contributions. 4. **Consolidated_Income_Statement**: Aggregation of segment revenues, COGS, R&D, SG&A, IPR&D charges, and tax to calculate Net Income. 5. **Working_Capital**: Schedules for accounts receivable, inventory, accounts payable, and accrued rebates. 6. **Depreciation_Amortisation_Capex**: Waterfall schedules for PP&E and intangible assets. 7. **Debt_Schedule**: Tranches of senior notes, commercial paper, interest expense calculations, and debt paydown logic. 8. **Balance_Sheet**: Assets, liabilities, and shareholders' equity, ensuring the model balances. 9. **Cash_Flow_Statement**: Operating, investing, and financing cash flows, linking Net Income to the ending cash balance. 10. **DCF_Valuation**: Unlevered free cash flow calculation, terminal value, and implied share price. ## Key Financial Relationships 1. Innovative Medicine Revenue = Prior Year Revenue x (1 + Volume Growth + Net Price Adjustment) - LOE Impact. 2. MedTech Revenue = Prior Year Revenue x (1 + Procedure Volume Growth) + Acquired Revenue. 3. Consolidated Revenue = Innovative Medicine Revenue + MedTech Revenue. 4. COGS = (Innovative Medicine Revenue x Innovative Medicine COGS %) + (MedTech Revenue x MedTech COGS %). 5. R&D Expense = Consolidated Revenue x Blended R&D Margin. 6. SG&A Expense = Consolidated Revenue x Blended SG&A Margin. 7. Operating Income = Consolidated Revenue - COGS - R&D Expense - SG&A Expense - Amortisation. 8. Accounts Receivable = (Consolidated Revenue / 365) x DSO. 9. Inventory = (COGS / 365) x DIO. 10. Accounts Payable = (COGS / 365) x DPO. 11. Interest Expense = Average Debt Balance x Weighted Average Interest Rate. 12. Free Cash Flow = Operating Cash Flow - Capital Expenditures. ## Cross-Sheet Dependencies The **Assumptions** sheet drives the growth rates and margin profiles in **Revenue_Innovative_Medicine** and **Revenue_MedTech**. These revenue sheets feed the top line of the **Consolidated_Income_Statement**. The Income Statement generates Net Income, which flows into the top of the **Cash_Flow_Statement** and updates Retained Earnings on the **Balance_Sheet**. The **Working_Capital** and **Depreciation_Amortisation_Capex** sheets calculate changes in assets and liabilities, feeding the operating and investing sections of the Cash Flow Statement. The Cash Flow Statement determines the cash available for debt service or share repurchases in the **Debt_Schedule**. The Debt Schedule calculates interest expense, creating a circular reference with the Income Statement, which must be managed with a toggle. Finally, the **DCF_Valuation** pulls operating profit and tax data from the Income Statement and capex from the Cash Flow Statement. ## Sign Convention - Revenue and growth rates are entered as positive numbers. - Expenses (COGS, R&D, SG&A, Interest) are entered as positive numbers in their respective build-up schedules but subtracted in the Income Statement formulas. - Assets are positive on the Balance Sheet. - Liabilities and Equity are positive on the Balance Sheet. - In the Cash Flow Statement, cash inflows are positive and cash outflows (e.g. Capex, dividends, debt repayment) are negative. ## Things Most Likely to Go Wrong 1. Failing to exclude the Consumer Health segment (Kenvue) from historical data prior to 2023, which will severely distort growth and margin trends. 2. Mismodelling the Stelara loss of exclusivity, which requires a specific negative adjustment to Immunology revenue rather than a generic growth rate. 3. Overlooking the impact of In-Process R&D (IPR&D) charges, which frequently depress GAAP earnings but should be excluded from adjusted operating margin calculations. 4. Ignoring the fair value inventory step-up from recent acquisitions (like Shockwave), which temporarily inflates COGS and depresses gross margins. 5. Miscalculating the talc litigation reserve, which creates massive one-time swings in GAAP net income and operating cash flow. 6. Applying a generic R&D percentage across both segments; Innovative Medicine requires significantly higher R&D investment than MedTech. 7. Forgetting to account for foreign currency translation, which can swing reported revenue by 2% to 4% annually. 8. Double-counting acquired revenue by applying organic growth rates to unadjusted historical base years that include partial-year acquisition contributions. ## Validation Checks 1. Consolidated Gross Margin should remain between 66% and 70%; flag if outside this band. 2. R&D Expense must be at least 14% of total revenue to reflect the company's innovation pipeline. 3. Total Assets must exactly equal Total Liabilities plus Shareholders' Equity in every forecast period. 4. The Debt/EBITDA ratio should remain below 2.0x to align with the company's AAA credit rating profile. 5. Operating Cash Flow to Net Income conversion should consistently exceed 1.0x. 6. The effective tax rate should be between 14% and 17%, reflecting statutory rates blended with R&D tax credits and international operations. 7. Dividend payout ratio should remain between 45% and 55% of adjusted net income. 8. MedTech revenue growth should not exceed 8% organically without a specific acquisition assumption being flagged. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Innovative Medicine Revenue Growth | 5.3 | % | Based on FY2025 operational growth excluding COVID-19 vaccine impacts. | | MedTech Revenue Growth | 5.4 | % | Based on FY2025 operational growth driven by electrophysiology and acquisitions. | | Gross Margin | 68.0 | % | Historical average, adjusting for recent inventory step-ups. | | R&D as % of Revenue | 15.0 | % | Consistent with historical investment levels required to sustain the pharmaceutical pipeline. | | SG&A as % of Revenue | 25.5 | % | Reflects historical averages and ongoing commercial launch expenses. | | Effective Tax Rate | 15.0 | % | Aligns with recent adjusted effective tax rates and global minimum tax impacts. | | Days Sales Outstanding (DSO) | 60 | Days | Calculated from recent accounts receivable and revenue trends. | | Days Inventory Outstanding (DIO) | 105 | Days | Calculated from recent inventory and COGS trends. | | Days Payable Outstanding (DPO) | 120 | Days | Reflects strong supplier negotiating power. | | Capex as % of Revenue | 3.5 | % | Based on historical capital expenditure levels. | | Dividend Payout Ratio | 50.0 | % | Consistent with the company's long-term dividend policy. | | Weighted Average Cost of Capital | 7.5 | % | Reflects the AAA credit rating and low-beta defensive nature of the stock. | | Terminal Growth Rate | 2.0 | % | Standard long-term GDP growth assumption for a mature, diversified healthcare company. | ## Data Sources & Benchmarks - SEC EDGAR for 10-K and 10-Q filings. - Johnson & Johnson Investor Relations website for earnings presentations and pipeline updates. - Key peers for benchmarking: Pfizer (PFE), Merck (MRK), AbbVie (ABBV) for Innovative Medicine; Medtronic (MDT), Stryker (SYK) for MedTech. - Industry data sources: IQVIA for prescription volume data, EvaluatePharma for pipeline probability and LOE schedules. - Consensus estimates: FactSet or Bloomberg for validation of near-term revenue and EPS forecasts. ## Sources - Johnson & Johnson Q4 and Full-Year 2025 Earnings Release (January 21, 2026) - Johnson & Johnson Q4 and Full-Year 2024 Earnings Release (January 22, 2025) - SEC Form 10-K and 10-Q filings for Johnson & Johnson (FY2024 and FY2025) - Macrotrends Gross Margin Historical Data - TradingView Financial Results Summaries - StockInvest.us Q1 2025 Financial Update --- ## Frequently asked questions ### What is Johnson & Johnson's primary business focus? Johnson & Johnson is a diversified global healthcare leader specializing in the research, development, manufacture, and sale of pharmaceutical products and medical devices. Its business is divided into Innovative Medicine, focusing on therapies like immunology and oncology, and MedTech, providing products for surgery, orthopaedics, and vision. ### What are the main revenue drivers for Johnson & Johnson? Johnson & Johnson's revenue is primarily driven by its Innovative Medicine segment, which focuses on intellectual property-heavy pharmaceuticals, and its manufacturing-intensive MedTech segment. Growth is expected from new pipeline assets and recent MedTech acquisitions, which are key to managing the revenue transition from legacy blockbusters. ### What is Johnson & Johnson's typical capital expenditure as a percentage of revenue? Johnson & Johnson's capital expenditure typically ranges from 3% to 4.5% of revenue. Approximately 60% of this capex is allocated to growth initiatives, such as expanding biologic manufacturing capacity and developing robotic surgery facilities, while the remaining 40% is for maintenance. ### How do Johnson & Johnson's intangible assets impact its balance sheet? Goodwill and intangible assets represent over 40% of Johnson & Johnson's total assets, reflecting its history of large acquisitions. This significant component is crucial for equity valuation and scenario planning, especially when considering the impact of M&A on the company's financial structure. ### What is the purpose of the downloadable Excel financial model for Johnson & Johnson? The downloadable Excel model serves as a comprehensive equity valuation and scenario planning tool for equity research analysts covering Johnson & Johnson. It specifically focuses on analyzing the revenue transition from legacy blockbuster drugs facing loss of exclusivity to new pipeline assets and recent MedTech acquisitions. ### How has Johnson & Johnson's business structure changed recently? Johnson & Johnson recently spun off its Consumer Health segment, Kenvue, in 2023, streamlining its focus on pharmaceuticals and medical devices. The company has also made significant acquisitions, including Abiomed, Shockwave Medical, V-Wave, and Halda Therapeutics, to strengthen its MedTech and pharmaceutical portfolios. [Interactive forecast calculator](https://finamodel.com/companies/johnson-johnson/forecast)